Equipment sharing among people who inject drugs (PWID) is a key risk factor in infection by hepatitis C virus (HCV). Both the effectiveness and cost-effectiveness of interventions aimed at reducing HCV transmission in this population (such as opioid substitution therapy, needle exchange programs or improved treatment) are difficult to evaluate using field surveys.
INTRODUCTION
In high income countries, people who inject drugs (PWID) are the main population at risk of infection with hepatitis C virus (HCV), with a seroprevalence ranging between 15% and 90%
(1). The risk of HCV transmission is high for all drug-equipment sharing that can lead to blood contact: injection equipment (syringes, cotton or cups (2)), straws (3) and crack pipes (4).
Risk reduction measures have been taken to reduce HIV and HCV transmission among PWID. These measures have focused mainly on opioid substitution treatments such as methadone and buprenorphine, and on needle exchange programs (5). However, other measures are possible. Indeed, some European countries have financed and launched supervised injection and needle exchange programs in prisons (6). Moreover, the landscape of therapy for HCV infection, where treatment was suboptimal until recently, is rapidly changing. More efficient and tolerable treatment strategies have become available. Prevircontaining regimens -already available -have significantly increased the chances of a sustained virologic response (SVR, i.e. undetectable levels of HCV for an extended period of time) for patients infected with genotype 1 HCV, the most prevalent HCV genotype in western Europe and North America among PWID (5, 7). Using these combinations, for patients treated for the first time, the SVR rate for genotype 1 reaches 70-75% vs. 50% for treatments with pegylated interferon and ribavirin (8) (9) (10) (11) (12) . Other, more effective pan-genotypic drugs that are used orally and may be prescribed for a shorter duration are at advanced stages of development (13, 14) . Given that non-viremic patients (i.e. those with a SVR) cannot transmit the infection (15), we are now considering the use of treatment as a means of preventing transmission of HCV in this population (« treatment as prevention »).
However, the implementation of harm reduction programs (HRP), like needle exchange programs, and the use of these new treatments to avoid transmission imply additional costs.
For optimal use of available resources, it is important to evaluate the effectiveness and costeffectiveness of these strategies. For this purpose, clinical studies and traditional epidemiological studies such as historical comparisons, cohorts and/or case-control studies encounter problems of feasibility, cost and time, especially in the PWID population, which is difficult to reach. Mathematical modeling is an alternative; indeed, it enables an estimation of the efficiency and cost of multiple strategies of harm reduction, screening and treatment effects upon HCV transmission within a short period of time. The main goal of the present article is to review mathematical models used to simulate transmission of HCV among PWID, and to evaluate their pros and cons.
The first section briefly summarizes the corpus of papers found. The second describes compartmental models and their properties. The third section describes individual-based models and their properties. The final section presents results obtained and recommendations for public health policies.
SEARCH STRATEGY AND SELECTION CRITERIA
The aim of the review was to identify dynamic mathematical models used for transmission of HCV among PWID in the literature and to evaluate their strengths and limits. Eligible studies had to satisfy two conditions: 1) describe a dynamic mathematical model for transmission of HCV; and 2) study a population of PWID. In accordance with Cochrane collaboration guidelines (16), we conducted our search in the Medline database using the keywords mathematical, model, hepatitis C and drug user and variations of these words. Our review takes into account the bibliographies of all identified publications and includes all items found until June 2014.
RESULTS
Of 214 articles identified, we examined 57 of them in details and keep 32 articles that fulfilled the above criteria (see Figure 1 for details about the reasons for exclusion). We added 5 articles coming from other sources, given a total of 37 original articles . The modeled populations were mainly from the United Kingdom (17-22, 26, 35, 36, 43, 45-48) , Australia (27, 31, 33, 43, 50, 51) and USA (30, 37-39, 49, 52) . Two articles involved analyses in developing countries: that of Durier et al. (25) studied a population of PWID in Vietnam, while Vickerman et al. (24) examined a population of PWID in Pakistan.
The main objectives of these studies were: (i) to present a model of transmission of HCV and provide analytical results concerning the mathematical properties of the model model (28, (35) (36) (37) (38) (39) ; (ii) to evaluate the impact of HRP (on the chronic/antibody prevalence, incidence, number of infections and quality adjusted life years (QALYs) gained) (21, 22, 24-26, 29, 33, 36-41, 50, 51) , (iii) to compare epidemics dynamic of HCV and HIV infections (1, 23, 24, 28, 33, 40-42, 44, 45) ; (iv) to evaluate the impact of treatment of HCV infection on transmission (17-19, 25, 34, 43, 49, 50) and cost (20, 43); and (v) to evaluate the impact of potential HCV vaccination strategy (30, 32, 51) . Objectives and main results of these articles are detailed in Table 1 .
Mathematical models used in the articles were divided into two categories: compartmental models and individual-based (or agent-based) models (IBMs). The assumptions underlying the two models and their strengths and weaknesses are presented in the following sections In addition, we distinguished two approaches in these articles: stochastic or deterministic. In the stochastic approach, the epidemic is considered as a chain of events (infections, recovery, etc.) occurring at random times among individuals. Thus, this approach takes into account the randomness of durations of the different health stages in the population. At each event, the transition that occurs is determined by probabilities induced by the global transition rates.
When dealing with large populations, averaging of randomness leads to deterministic evolutions that can be described by ordinary differential equations (54). For further explanation about the advantages and weakness of these two approaches, the reader can refer to (55).
COMPARTMENTAL MODELS Description
Compartmental models were the most frequently used class of models for HCV epidemic simulation among PWID with 31 of the 37 articles in our review (see Table 1 ). They considered transmission of HCV infection at the macroscopic scale, dividing the population into compartments corresponding to different states of the infection process: susceptible, infectious, recovered, etc. (54, 56) . Transitions from one state to another were based on rates that could be time dependent.
For instance, Figure 2 presents a model we have recently developed for HCV transmission in PWID (57). The population is distributed in eight compartments associated with HCV infection and care status. Susceptible PWID are separated into two categories: new and experienced injectors, as recently initiated injectors are at higher risk of infection (58). When infected, they progress to acute hepatitis that can lead either to spontaneous recovery (and PWID become susceptible again) or to undiagnosed chronic hepatitis C. Infected patients could be diagnosed, and progress to diagnosed & non-linked to care hepatitis C stages. They are then linked to care and lost to follow-up, or treated. When treated, patients may respond to treatment and return to a susceptible state, or not respond and progress to a non-SVR state.
Transitions between different compartments or states are governed by annual transition rates that may be time-dependent. For example, rates of infection depend on the current proportion of infected PWID in the population.
Other published models include more compartments or less compartments according to the objectives and available data. The most parsimonious models include only two compartments: susceptible and infectious (28, 33, (37) (38) (39) . Some authors included in their model the uncertain immunization (59) of previously infected PWID against re-infection (18, 19, 21, 24, 35, 45 (27, 47, 48) . Finally, in order to estimate the cost of the infection or the consequences of HCV infection on the population's health, some authors included additional compartments of natural history of chronic hepatitis C (20, 52).
Strengths and limits
Compartmental models have the advantage of not needing intensive computation time. In large populations, the trajectory of the epidemics can be described by a system of ordinary differential equations (55). However, they are based on two important hypotheses.
First, the population of a compartment is supposed to be homogeneous. The only characteristic of an individual is the compartment in which he/she is located. Thus, parameters that define an individual are parameters that are derived from the overall population; they can be easily interpreted in term of epidemiology and obtained from epidemiological studies. This is not necessarily the case for individual-based models (IBMs; see below). For example, the infection rate represents the force of infection in the population, for which estimations are available for HCV among PWID (58). However, PWID population is highly heterogeneous.
There is a variability of individual characteristics and behaviors, which can impact the risk of infection by HCV or HCV-infected patients care. Indeed, the high variations of infection risk among PWID are due to differences in injection frequency, numbers of syringe sharing and number of sharing partners (60). Moreover, response rates to HCV treatment are different according to HCV genotypes. With a pegylated interferon + ribavirin regimen, SVR is around 75 for naïve patients infected with genotypes 2 or 3; and around 50% for naïve patients infected with genotype 1 (8-12). One may hypothesize that this could lead to the selection of hard-to-treat genotypes, and thus to a large proportion of prevalent cases infected with genotype 1. For simplicity, most of the published models do not differentiate genotypes; and consider only an average duration of treatment and SVR rate in the population. Cipriano et al.
study represents an exception, differentiating genotypes 1-4 of genotypes 2-3 (52).
Nevertheless, with the availability of highly effective pan-genotypic anti-HCV regimens not differentiating genotypes will no more be a problem. Some other characteristics are known to impact HCV transmission or treatment success: time since first injection, as the risk of transmission is higher in recent frequent injectors (58); substitution therapy with reduced risk of transmission from those who receive substitution (61); gender, as the spontaneous recovery rate is higher in women (62); HIV-HCV co-infection, associated with lower treatment success (63), imprisonment, as a history of injection in prison increase the risk of infection (64), and even genetic characteristics, with the IL28B polymorphism impacting the treatment response (65). Stratification of the population into different risk groups is a solution for relaxing the hypothesis of homogeneity of PWID (21-25, 27, 29, 36, 40-45 Secondly, the infection rate is often based upon the hypothesis that the population is totally mixed, in the sense that each susceptible individual can potentially be infected by any infectious person: in classical models, the infection rate per susceptible individual βI (t) increases with the number of infected persons in the population. This hypothesis seems to be poorly suited for describing infectious contacts with a blood-borne pathogen among PWID. partners/IDU, with a median duration of 3 years for a partnership, and they found that HCV phylogeny was associated with the injection network (67). These results suggest that the number of potential infectious contacts is restricted to a small group for each infected PWID, which slows the transmission of the virus in the population. However, they are based on a snapshot, and give no indication at a lifetime scale. In addition, Hahn et al. suggest that because of the high number of injecting partners the turnover of the injecting partners may be sufficiently high to consider that a totally mixed population is a valid hypothesis (30). An alternative approach chosen by several authors to relax this hypothesis in compartmental models is to include assortative mixing: they varied the mixing of the different risk groups.
Fourteen articles in the present review among the 31 compartmental models took into account assortative mixing in the population according to risk groups (21-24, 40, 42-45, 48) , substitution therapies (25, 27), experience as injector (46) or age (47). However, this solution does not enable taking into account small subgroups at the individual or community scale (injecting partners groups), but only groups at a population scale. developed an IBM to take into account different behaviors and levels of risk exposure in the population (30). The authors distinguished two practices at risk: risky needle sharing (RNS) and ancillary equipment sharing (AES); the probability of infection varied based on the level of risk exposure (corresponding to frequencies of RNS and AES) and HCV stage of the partner (higher infectivity during acute infection). Hutchinson et al. and Rolls et al. presented IBMs that took into account the social network of the population (see below) (26, 31, 50) .
INDIVIDUAL-BASED MODELS

Modeling contact network
The network of contacts can be represented by a graph, i.e. a set of vertices representing individuals and interconnected by a set of edges representing potentially infectious contacts between them (see example Figure 3 ).
Various network models have been described in the literature ( (71) have used a dynamic network model with a turnover of sharing partners for each individual each year. Two variants of turnover were tested: a turnover totally at random, and a turnover with some stability in injecting partners groups, with few differences between the results in these two settings. These dynamic models are however not be supported by data. 
MAIN RESULTS OF THE REVIEWED PAPERS
The objectives of articles on HCV transmission among PWID are numerous. However, important results consistently emerge.
Vaccination
The potential effect of a vaccination against HCV was evaluated in three articles. 
Harm reduction policies
The first author to take an interest in estimating the impact of harm reduction by a model was years. However, the authors underlined that the cost saving is mainly due to HIV infections averted.
HCV treatment
The impact of HCV treatment on transmission is considered to be effective despite the risk of reinfection (17, 19, 25, 34) . Some authors recommended specific targets and application modalities. Zeiler et al. studied the impact of HCV treatment in Australia, taking into account methadone maintenance therapy (27). The main concern of that paper was to determine the optimal distribution of treatment in the population. The results suggested treating active PWID rather than PWID under methadone maintenance therapy, with the hypothesis of equal adherence to treatment in the two groups. Their results showed that treating active PWID and ex-or non-PWID was cost-effective, but for a chronic prevalence below 60%; treating active PWID was more cost-effective because of avoided re-infection. This result remained valid even with a SVR rate in active PWID that was 50% lower than that of ex-or non-PWID (which may reflect lower adherence to treatment).
Martin et al. estimated the impact of a coming direct-acting antiviral, with treatment of shorter duration and with a higher tolerability (43). They compared efficiency and cost in three different geographic settings: Edinburgh, Melbourne and Vancouver. The study showed that halving the chronic prevalence after 15 years would be extremely expensive, particularly in Melbourne and Vancouver (around $50 million) where the chronic prevalence is high.
Finally, in Australia, Rolls et al. targeted infected individual for treatment initiation according
to their neighbors on the social network, with strategies including random treatment delivery, priority by node degree, treatment of the primary contacts of infected nodes, treatment of primary and secondary contacts of infected nodes, and treatment of treatment of the primary contact of uninfected nodes (50). They found that strategies including the treatment of primary and secondary contacts of some infected PWID randomly chosen for treatment ("ring" treatment) are the most effective strategies for a similar number of treatment starts.
CONCLUSION
To date, several different models have been used to study transmission of HCV among PWID.
Most of them were built to answer a specific question taking into account only the characteristics of PWID that pertained to that question, and thus averaging the non-relevant 
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Bram for linguistic revisions of the text. The syringe exchange program is effective and cost-effective when R0 is low (2.9 for HIV), but becomes less effective when R0 is high (6.9 for HCV) and cost become prohibitive (>250.000$ per averted infection), which is more realistic (in short-term analysis). This is necessary to combine syringe exchange program with intervention aimed at decreasing the R0, such as the methadone maintenance program. The short-term incidence underestimates the effectiveness of a program of long-term syringe exchange if the steady-state prevalence, in the absence of intervention, is below 50%. Conversely, if it is over 50%, the short-term incidence overestimates effectiveness.
STATEMENT OF INTERESTS
Murray et al. The estimated seroprevalence in the 90s was lower than currently observed. This result can be corrected by increasing viremia during the acute phase, which could confirm the higher rate of viremia during that period.
Current public health messages (not sharing needles) are inadequate for HCV (but effective for HIV). The authors propose encouraging PWID to share with only a small group of trusted persons (tested negative) and predict that by reducing the mean number of partners to one (vs. If a reduction of needle sharing is the only effet of the supervised injection facility: incremental net savings of almost $14 million and 920 life-years saved after 10 years.
When adding an increase use of safe injection pratices and increased referral to methadone maintenance treatment: incremental net savings of almost $18 million and 1175 life-years saved after 10 years.
The cost saving is mainly due to HIV infections averted. The spontaneous clearance has a local effect (i.e. around the concerning individual) on infection risk and the total number of spontaneous recovery has a global effect on the incidence of both primary and re-infection rates Network-based treatment strategies that chose PWID and treat their contact are most effective and allow to reduce the number of treatment needed to achieve a desired effect 
. Each node represents a PWID, and a tie is drawn between the injecting partners in the previous 3 months. Data courtesy of DA Rolls.
